Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Hill, Alan Colowick, Jean Nichols, Donald Hayden, John Biondi, Kevin Teo, Clara Mak, Robert McMahan Jr., Gordon Brandt, Bruce York

Woburn, Mass., Biotech Loses its President/CEO to Georgia Pharmaceutical Company
Stephen Hill will leave Woburn, Mass., biotech company ArQule, where he is president and CEO, next month for a similar position with Solvay Pharmaceuticals, the Marietta, Ga.,-based subsidiary of Brussels-based Solvay.
ArQule, which announced Hill’s departure on Jan. 30, said he will remain with that company through the end of March while it concludes its search for a successor. ArQule announced Jan. 7 that it began such a search, after Hill told the company’s board of directors he intended to leave the company.
Hill has served as president and CEO of ArQule since 1999. Previously, Hill headed global drug development at F. Hoffmann-La Roche from 1997 to 1999. He joined Roche in 1989 as medical adviser to Roche Products in the UK, and held several senior positions there that included UK medical director and head of international drug regulatory affairs at Roche headquarters in Basel, Switzerland. Hill is a fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University.
At Solvay, Hill will take office April 1. He will succeed Laurence Downey, who “has elected to retire from the company” effective April 30, according to a Solvay statement.
Downey joined Solvay Healthcare in Southampton, UK, in 1979 as a medical advisor. Seven years later he moved to Solvay Pharmaceuticals, where he initially served as vice president of medical services. Downey subsequently held positions as senior vice president of commercial operations and interim president and CEO. He later served as president and CEO of Solvay Pharma in Canada prior to rejoining Solvay Pharmaceuticals in the US as president and CEO in 2006.

Geron Oncology President Joins Cambridge, Mass., Pharmaceutical as CEO
Alan Colowick has been appointed CEO of Gloucester Pharmaceuticals and a member of its board of directors. Colowick, a medical doctor, previously served as president of oncology for Geron and earlier served as chief medical officer at Threshold Pharmaceuticals.
Before joining Threshold, Colowick held various management positions with Amgen, the highest being vice president of European medical affairs, where he oversaw products in hematology-oncology, nephrology, and internal medicine. While at Amgen, Colowick led the team responsible for the successful registration and launch of Aranesp in the US, the European Union, and Australia.
Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Brigham and Women's Hospital/Dana Farber Cancer Institute. He holds a BSci degree in molecular biology from the University of Colorado, an MD degree from Stanford University, and an MPH degree from Harvard University.
Gloucester also announced that it has promoted Jean Nichols to president and chief operating officer, from executive vice president and chief scientific officer; and that it has named Donald Hayden, a former executive vice president of Bristol-Myers Squibb and president of its Americas operations, chairman of its board of directors.
Headquartered in Cambridge, Mass., Gloucester Pharma is a privately held pharmaceutical company focused on developing drugs for treating cancer.

Madison, Wis., Economic Development Group Names Tech Executive as 2008 Chairman
John Biondi, president of C5-6 Technologies, a developer of biomolecules used in the production of biofuels, has been named 2008 chairman of Thrive, an economic group serving the Madison, Wis., region by promoting the growth of biotechnology and healthcare, as well as agriculture, nanotechnology, and information technology.
Thrive serves Wisconsin’s Columbia, Dane, Dodge, Green, Iowa, Jefferson, Rock, and Sauk counties.
Biondi — who served as vice chairman of Thrive last year — was previously an executive with Lucigen, which spun off C5-6, and nPoint.

Chinese Biopharmaceutical Company Names New Chief Financial Officer

Kevin Teo has been named chief financial officer of 3SBio, a biopharmaceutical company based in Shenyang, China. Teo succeeds Clara Mak, who the company said “is resigning for personal reasons” after leading the company through the initial public offering process; Mak will stay with 3SBio until Feb. 29 “to assist with the transition.”
Teo’s appointment took effect Jan. 28.
He most recently served as group business controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing, and Beijing. Earlier, Teo held senior roles at Huawei Technologies Company Ltd. of Shenzhen, Siemens Malaysia, Siemens Cerberus, Wetlands International - Asia Pacific, Chua Song Seng, and Anuarul Azizan Chew and Co.
Teo received a London Chamber of Commerce and Industry Third Level Group Diploma in Cost Accounting and a Pitman Certificate in Advanced Accounting in 1989. He also received a master of laws degree in international business law from the School of Law of Staffordshire University in the UK.

WCU's Kimmel School Taps NC Gov. Easley's Science/Technology Advisor as Dean
Robert McMahan Jr., senior adviser for science and technology to North Carolina Gov. Mike Easley and executive director of the North Carolina Board of Science and Technology, will be leaving those posts to become dean of Western Carolina University’s Kimmel School of Construction Management and Technology.
McMahan’s appointment takes effect “prior to April 1,” WCU said in a Jan. 25 statement announcing the appointment.
In addition to advising the governor, McMahan’s current job includes providing counsel on science and technology issues for NC secretary of commerce Jim Fain, as well as for the General Assembly and NC Economic Development Board. McMahan also serves as a primary liaison on science, technology, university research capacity and structure, entrepreneurship and technology-based economic development to the University of North Carolina and state community college systems, the NC Small Business and Technology Development Center, the NC Biotechnology Center, and numerous entrepreneurial associations.
McMahan also holds the position of research professor of physics and astronomy at the UNC at Chapel Hill, where he teaches and conducts research in cosmology, and he serves as an adjunct professor in the department of textile and apparel technology and management in North Carolina State.
Until joining state government in 2003, McMahan was a senior technology strategist and venture capitalist for In-Q-Tel, a private venture capital organization funded by the CIA, where he was responsible for developing a technology investment strategy for the intelligence community. Before joining In-Q-Tel, he served as executive vice president of engineering and research and development for GretagMacbeth.
McMahan earned bachelor’s degrees in physics and the history of art from Duke University in 1982, a doctoral degree in physics from Dartmouth University in 1986, and completed postdoctoral studies at the Harvard University/Smithsonian Astrophysical Observatory Center for Astrophysics in 1989.

Bothell, Wash., Biopharmaceutical Promotes EVP to President, Names New Secretary/Interim CFO
Gordon Brandt has been promoted to president of Nastech Pharmaceutical, a biopharmaceutical company in Bothell, Wash.
Nastech's chairman and CEO, Steven Quay, siad in a press release the move will allow him to establish a spinout business, MDRNA, as an independent company concentrating on the development of RNA-based therapeutics.
Brandt had served as executive vice president of clinical research and medical affairs since joining Nastech in November 2002. From 1997 to 2002, Brandt worked at Sonus Pharmaceuticals, a developer of oncology drugs, where he held the positions of vice president of clinical and regulatory affairs, and director of medical affairs.
Brandt graduated from Yale University with a BSci degree in engineering science, received an MD degree from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco.
Nastech also announced the appointment of Bruce York as secretary and interim chief financial officer. He replaces Philip Ranker, who resigned Jan. 4.

South Carolina BIO CEO Resigns to Take Clemson Post Overseeing Biotech Partnerships
Karl Kelly has resigned as CEO of the South Carolina Biotechnology Industry Organization to join Clemson University to develop public-private partnerships for biotechnology as well as for the university’s Restoration Institute. Kelly began his new positions Feb. 1.
Kelly will remain active with SC BIO as a consultant, allowing him to continue promoting human genetics-nutrition research at the Greenwood (SC) Genetic Center, as well as biofuels and transgenic plant research at the Pee Dee Research and Education Center in Florence, SC. He also will encourage rural economic development through the Clemson Institute for Economic and Community Development in Columbia, SC.
Kelly’s duties include developing partnerships for Restoration Institute programs in advanced materials, community revitalization, historic preservation, renewable energy, and restoration ecology.
He has served as CEO of SC BIO since its formation. Prior to that, he served as senior vice president of sales and marketing at Suitt Construction, executive vice president of the Birmingham Metropolitan Development Board, director of business development for Fluor Daniel Biotechnology and Pharmaceuticals, coordinator of real estate and facility planning for Genentech, and project director for Fluor Daniel siting and consulting services.
Kelly holds a bachelor’s degree in political science and a master’s degree in city and regional planning, both from Clemson University.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.